1. Home
  2. ANL vs OSPN Comparison

ANL vs OSPN Comparison

Compare ANL & OSPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

SELL

Current Price

$10.00

Market Cap

998.8M

Sector

N/A

ML Signal

SELL

Logo OneSpan Inc.

OSPN

OneSpan Inc.

SELL

Current Price

$22.79

Market Cap

946.7M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
ANL
OSPN
Founded
2004
1991
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
946.7M
IPO Year
2022
2000

Fundamental Metrics

Financial Performance
Metric
ANL
OSPN
Price
$10.00
$22.79
Analyst Decision
Strong Buy
Hold
Analyst Count
7
4
Target Price
★ $29.50
$23.50
AVG Volume (30 Days)
229.1K
★ 901.4K
Earning Date
08-14-2026
10-29-2026
Dividend Yield
N/A
★ 2.33%
EPS Growth
N/A
★ 28.77
EPS
N/A
★ 0.68
Revenue
N/A
★ $243,180,000.00
Revenue This Year
$243.83
$5.28
Revenue Next Year
N/A
$2.44
P/E Ratio
★ N/A
$32.60
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$10.07
52 Week High
$17.25
$27.45

Technical Indicators

Market Signals
Indicator
ANL
OSPN
Relative Strength Index (RSI) 41.78 58.63
Support Level $8.95 $21.29
Resistance Level $11.75 $27.45
Average True Range (ATR) 1.03 1.27
MACD 0.20 -0.15
Stochastic Oscillator 42.35 42.09

Price Performance

Historical Comparison
ANL
OSPN

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About OSPN OneSpan Inc.

OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.

Share on Social Networks: